Abiraterone, cabazitaxel, enzalutamide have been developed in parallel and studies cannot be compared. Is there an optimal sequence of these drugs? What is the impact of AR exhaustion on the efficacy of taxanes? Do we have predictors of response to AR-targeted agents and taxanes? Is there cross-resistance between AR targeted agents?
Conclusions of the Dutch Society of Medical Oncology for 2013 will be provided.
Content taken from a Sanofi sponsored satellite symposium at ESMO 2013 as part of the official programme.